Gland Pharma To Invest Rs 400 Crore In Telangana

Gland Pharma has announced an investment of over Rs 400 crore in Genome Valley, Hyderabad, to include additional capabilities to its existing facility to manufacture biologicals, biosimilars, antibodies and recombinant insulin.

The company had established its biopharmaceutical facility in February 2022 at Genome Valley with an investment of Rs 300 crore to manufacture vaccines, biologicals, biosimilars, antibodies and others. 200 persons have already been hired for the facility. The expanded facility may be able to employ more than 500 more qualified, skilled and semi-skilled workforce, mostly from the nearby places.

The expanded site will focus on meeting national and international regulations in the manufacturing of the biological products, and will be built under the GMP guidelines applicable for the respective product lines.

The announcement was made on Monday after minister K T Rama Rao's meeting with the Managing Director and Chief Executive Officer of Gland Pharma, Srinivas Sadu.

Senior government officials including the Principal Secretary of the Industries and Commerce Department Jayesh Ranjan and Chief Executive Officer of Telangana Lifesciences Shakthi M Nagappan were also present during the meeting.

Minister Rao said, "I am delighted that Gland Pharma will be investing Rs 400 crore in expanding its footprint in Hyderabad and will create 500 more jobs in the State. I am also excited that the expansion will be focused on advanced areas like biologicals, biosimilars, antibodies and recombinant insulin, all of which are areas where the State is focused on building capabilities and on consolidating its leadership position. This expansion truly demonstrates the strength of the life sciences ecosystem in the city and Genome Valley."